The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi
about
Monoclonal antibody form and function: manufacturing the right antibodies for treating drug abuseRecombinant antibody production evolves into multiple options aimed at yielding reagents suitable for application-specific needsNanobodies as novel agents for cancer therapy.Llama-derived single-chain antibody fragments directed to rotavirus VP6 protein possess broad neutralizing activity in vitro and confer protection against diarrhea in mice.A V H H that neutralizes the zinc metalloproteinase activity of botulinum neurotoxin type AMetabolic peculiarities of Aspergillus niger disclosed by comparative metabolic genomicsBotulinum neurotoxins and botulism: a novel therapeutic approach.Refolded scFv antibody fragment against myoglobin shows rapid reaction kinetics.Single-domain antibodies and their utility.Single Chain Variable Fragments Produced in Escherichia coli against Heat-Labile and Heat-Stable Toxins from Enterotoxigenic E. coli.Inclusion bodies as potential vehicles for recombinant protein delivery into epithelial cells.Achieving efficient protein expression in Trichoderma reesei by using strong constitutive promoters.A Recombinant Human Anti-Platelet scFv Antibody Produced in Pichia pastoris for Atheroma Targeting.Microbial factories for recombinant pharmaceuticalsHigh-yield production of functional soluble single-domain antibodies in the cytoplasm of Escherichia coli.Design and production in Aspergillus niger of a chimeric protein associating a fungal feruloyl esterase and a clostridial dockerin domain.Biotechnological applications of recombinant single-domain antibody fragments.Expression of recombinant antibodies.Microbials for the production of monoclonal antibodies and antibody fragments.Advances and applications of molecular cloning in clinical microbiology.Recombinant protein production by in vivo polymer inclusion display.Microbial platform technology for recombinant antibody fragment production: A review.Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.Production in yeast of pseudotype virus-like particles harboring functionally active antibody fragments neutralizing the cytolytic activity of vaginolysin.Cell engineering and molecular pharming for biopharmaceuticals.Applying Unconventional Secretion in Ustilago maydis for the Export of Functional Nanobodies.The scientific impact of microbial cell factories.A new approach to studying ion uptake by actinomycetes.Genetic fusion of single-chain variable fragments to partial spider silk improves target detection in micro- and nanoarrays.Efficient expression of the anti-AahI' scorpion toxin nanobody under a new functional form in a Pichia pastoris system.Efficient heterologous expression and secretion in Aspergillus oryzae of a llama variable heavy-chain antibody fragment V(HH) against EGFR.Evolution of Therapeutic Antibodies, Influenza Virus Biology, Influenza, and Influenza Immunotherapy.
P2860
Q24632128-AB661DC7-4326-4CFD-B27D-07840C13E890Q26795434-31FB3EE6-D842-48B1-AA59-898760FBD12FQ30778309-39F9716A-E03A-4FE7-83F5-8BB86DC34251Q33352435-24B23865-0B26-478F-BF3A-77C0A3AA1C09Q33525766-A1BB1EDC-CE26-4AF0-8B0F-74A02B812C2AQ34006376-51129977-58FD-4697-A802-C54BA19494ABQ34070659-9CE86E2F-E242-4E7B-8FED-F7C0298D93C3Q34835964-FC3D4C29-FF02-4680-88CA-A187D24A0E5AQ35089545-E7A30274-9BCE-4F9E-8B2E-BAA4169C4C03Q35685836-3ECF1890-D5C1-45D0-A6E8-D8E56E54B7EFQ36209585-CC7A5368-0D12-459F-AB00-36B20EDAB042Q36226608-BACF357B-4F62-4E1D-BE4D-BEF91ACDC0A4Q36261019-50BACD8F-903C-4292-83CE-C2C0DEFC26A0Q37160231-99C696B0-B61F-4B9C-8856-E11A65F6685DQ37283860-AA364B67-74FB-43F4-BCBD-E06DA648D1ECQ37701854-2A6764FE-F557-478B-8BC5-1329067AE133Q37887077-16406257-1DA0-48B9-9137-6E8137C05EC1Q38126016-ED2E15EA-4D94-437E-8A1F-E09613AB8D36Q38159015-8A6D7EBB-1E7F-4C40-9D25-4BAF9E342A69Q38229428-7C094EDB-8224-40FB-BE42-EC86EDB996C2Q38628960-68D4FF29-C174-4784-AE62-4E1D2B58E7E4Q38888751-B1829FF3-8914-4951-84EE-BFDD53350059Q39109310-5DDA736E-56E9-4F48-9C9E-4188B7C03DD6Q39428042-4E7D6A60-86CF-499A-855C-F8561897BDCAQ40139717-420E44C9-3393-47AA-9612-158AE8B5AEAFQ42142070-E9A1F45B-7596-4CA0-8E13-DF7EA2CB8AEDQ43194023-88A9BDE3-3801-404E-BB4C-257DBC618BB8Q44262169-EBA01A56-1CE8-4861-AA21-89BF907D79F3Q54258743-0E8CEF46-C8CD-4FBE-9774-C3E88F7CCD91Q54342332-1E505F33-F4AB-49A1-8B54-68F2EB4C7DA6Q54508166-7C15B1B7-24CE-4510-A926-5508B57CEADFQ55554478-FE2EC12A-9324-44AD-8F9E-05CBE596BEF1
P2860
The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The production of antibody fra ...... y yeasts and filamentous fungi
@ast
The production of antibody fra ...... y yeasts and filamentous fungi
@en
The production of antibody fra ...... y yeasts and filamentous fungi
@nl
type
label
The production of antibody fra ...... y yeasts and filamentous fungi
@ast
The production of antibody fra ...... y yeasts and filamentous fungi
@en
The production of antibody fra ...... y yeasts and filamentous fungi
@nl
prefLabel
The production of antibody fra ...... y yeasts and filamentous fungi
@ast
The production of antibody fra ...... y yeasts and filamentous fungi
@en
The production of antibody fra ...... y yeasts and filamentous fungi
@nl
P2093
P2860
P356
P1476
The production of antibody fra ...... y yeasts and filamentous fungi
@en
P2093
Cees AMJJ Van Den Hondel
Christien Lokman
Peter J Punt
Vivi Joosten
P2860
P2888
P356
10.1186/1475-2859-2-1
P407
P577
2003-01-30T00:00:00Z
P5875
P6179
1001818532